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ABSTRACT     
Tuberculosis remains the top killer from an infectious disease worldwide. Early and accurate diagnosis 
and detection of drug sensitive and drug resistant tuberculosis is essential for achieving global 
tuberculosis control.  Despite the rollout of the Xpert® MTB/RIF assay as the first-line rapid tuberculosis  
diagnostic test, the gap between global estimates of incidence and new case notifications remains 4·1 
million. More accurate, rapid and cost-effective screening tests are needed to improve case detection. 
Diagnosis of extrapulmonary tuberculosis, tuberculosis in children, people living with HIV and in 
pregnant women remains particularly problematic. The diagnostic molecular technology landscape has 
continued to expand, including the development of tests for resistance to several anti-tuberculosis 
drugs.  Biomarkers to indicate progression from latent infection to clinical disease, to predict risk of re-
activation after cure and to provide accurate endpoints for drug and vaccine trials are urgently needed. 
Sophisticated bioinformatic computational tools and systems biology approaches are being applied to 
the discovery and validation of biomarkers with substantial progress taking place. New data have been 
forthcoming through the study of T-cell responses and T cell function, serological studies, flow-
cytometric based assays, protein and gene expression studies. Alternative diagnostic strategies include 
non-sputum based detection with breath-based tests and automated digital radiography under 
investigation as potential screening and triaging tools. We review recent developments and key 
achievements in the search for new tuberculosis diagnostics and biomarkers. We highlight current gaps 
and challenges, and prioritise areas needing further investment, including impact assessment and cost 









We searched reports published in English between January 1, 2013 and December 1, 2017 in PubMed, 
Google Scholar, Cochrane Library, Embase, and websites of tuberculosis related international 
organisations (WHO, FIND, STOP TB Partnership, TAG, TB Alliance, Consortium for TB biomarkers (CTB2), 
NIH-NIAID)  with the terms “tuberculosis”, “Mycobacterium tuberculosis”, “Latent TB” plus 
“diagnostics”, or “biomarker”,  “gene expression”, “micro-RNA”, “proteomics”, “metabolomics”, 
“imaging”, “interferon gamma release”, or “clinical trial”.  We also reviewed studies cited by articles 
identified by this search strategy and selected those that we identified as relevant. We also collated and 
synthesised information on the development of new tuberculosis diagnostics and biomarkers through 
communications with various stakeholders. Some review articles are cited to provide readers with more 















Box 1 Key points 
 
 Tuberculosis is the world’s major cause of death from a single infectious disease. 
 Rapid and accurate detection of tuberculosis is essential for guiding treatment yet case 
detection and reporting rates remain low with 40% of estimated incident cases failing to be 
diagnosed and notified.   
 Rollout of the GeneXpert® MTB/RIF assay has not improved global case detection rates and 
alternative screening and diagnostic tools are needed to assist active case finding that are 
affordable and suitable for use in settings with few resources. 
 A range of technologies are being developed and the majority of rapid diagnostic products close 
to introduction are based on the detection of mycobacterial nucleic acids.  
 Next generation sequencing is improving knowledge of drug resistance mutations.  
 There is an urgent requirement for biomarkers that can be used to  differentiate tuberculous 
disease from latent infection, to predict the risk of progression to clinical disease, and to provide 
accurate endpoints for clinical trials of new drugs and vaccines 
 Progress is being made in the search for biomarkers of infection and active tuberculosis disease.  
 Obstacles to the production and marketing of new detection platforms are considerable, the 







During 2016 there were an estimated 10·4 million incident cases and 1·7 million deaths due to 
tuberculosis.1  Rapid and accurate detection of tuberculosis is essential for guiding treatment yet case 
detection and reporting rates remain low with 40% of estimated incident cases failing to be notified. 
Under-diagnosis remains a problem, particularly in countries where patients face substantial geographic 
and socioeconomic barriers when accessing health care. In most countries with a high burden of 
tuberculosis case detection relies on self-reporting of symptomatic patients to a health care facility. 
Delays in accessing effective treatment provides increased opportunity for transmission and 
continuation of the epidemic. Detecting extrapulmonary forms of the disease and tuberculosis in 
children is particularly problematic. Access to tests for drug resistance remains inadequate. In 2016 only 
33% of bacteriologically confirmed new (not previously treated) tuberculosis patients were tested for 
resistance to rifampicin. Of patients that had previously received anti-tuberculosis treatment for at least 
one month and who are considered at higher risk of resistance 60% were tested.1  Average treatment 
success rates during 2016 were 83% but outcomes were considerably poorer for drug resistant disease. 
In 2014 treatment success rates of 54% and 30% were reported for MDR-TB (resistance to at least 
isoniazid and rifampicin) and XDR-TB (additional resistance to the fluoroquinolones and second line 
injectable drugs) respectively.1   
The WHO-recommended rapid diagnostic test for detection of tuberculosis and rifampicin resistance is 
an automated polymerase chain reaction (PCR) assay with an integrated semi-automated sample 
extraction device. The GeneXpert® MTB/RIF assay (Cepheid Inc, Sunnyvale, USA) was endorsed by WHO 
in 2010. Roll out of the new technology has been facilitated by preferential pricing deals for public 
sector use in countries with a high tuberculosis burden. However, access remains limited and there are 
concerns about long term sustainability in countries that are dependent on donor support. New tools for 
screening and diagnosing tuberculosis are required that are affordable and suitable for use in poorly 
resourced communities.  
There is an urgent requirement for biomarkers that can be used to detect tuberculosis disease and 
differentiate it from latent infection. In addition, markers that predict the risk of progression to clinical 
disease would greatly aid efforts to eradicate the disease and indicators of likely treatment failure and 




endpoints for clinical trials of new drugs and vaccines. The pathology of Mycobacterium tuberculosis 
(MTB) infection and the host response is highly complex and not fully understood.  Holistic systems 
biology approaches are being applied with sophisticated computational and mathematical 
methodologies. Recently, new data have been forthcoming through study of T-cell responses and T cell 
function, serological studies, flow-cytometric based assays, protein and gene expression studies.  We 
present an overview of recent developments and key scientific achievements in the search for new 
tuberculosis diagnostics and biomarkers, summarising the portfolio of rapid diagnostics tests in 
development and literature pertaining to potential biomarkers as of December 1st 2017.  The scientific, 
operational and resource challenges are also reviewed. Further sources of information and links to 
relevant WHO polices are listed in the online appendix 1 (page 1).  
 
CURRENT STATUS OF TUBERCULOSIS DIAGNOSTICS 
Sputum microscopy to identify MTB acid fast bacilli remains the most commonly performed tuberculosis 
test. It is a low-cost test that can be performed in basic laboratories attached to primary health care 
clinics. It has low sensitivity and examination of multiple samples is recommended.  Sensitive tests for 
tuberculosis such as culture and tests for drug resistance have historically been based either in specialist 
centres or reference laboratories which are not accessible to the bulk of the population. 
Figure 1 shows key stages in the development, production and adoption of a new tuberculosis tests. 
Online appendix 1 (pages 2 and 3) provides further details of the technology, target market and links to 
further information. Concerns regarding the sale of substandard in vitro diagnostic assays led the 
tuberculosis program at the WHO to initiate a process of endorsing tuberculosis tests. Published 
performance data and information provided by the manufacturers is reviewed by a committee of 
experts and recommendations are made as to their use. Liquid culture systems and Line Probe Assays 
(LPAs) for detection of drug resistance were endorsed, but a negative endorsement was declared for 
serological tests because of their poor sensitivity and specificity. 2   
The Cepheid Xpert® MTB/RIF WHO recommendations for the use of chest X-ray in tuberculosis triaging, 
screening and diagnosis are provided in 
(http://apps.who.int/iris/bitstream/10665/252424/1/9789241511506-eng.pdf?ua=1). ® MTB/RIF offers 
for the first time rapid access to testing for resistance to rifampicin, a marker for MDR-TB. The assay was 




but the recommendation has since been broadened to replace microscopy as a first-line diagnostic and 
for the detection of some forms of extra pulmonary disease.3  Although easy to use, the technology is 
sophisticated and expensive. Reduced pricing is available to the public sector of 145 low and middle-
income countries with a high burden of tuberculosis. A GeneXpert machine costs from USD 12,000 to 
USD 71,000 dependent on the number of test modules incorporated and a single-use test cartridge is 
USD 9.98 [http://www.stoptb.org/global/awards/tbreach/bet.asp]. The test requires a constant source 
of electricity and is vulnerable to heat and dust and high rates of instrument failure have been reported 
in some settings.4,5 Initial roll-out of the technology was via centralised or reference laboratories. To 
catalyse uptake at lower levels of the health system from 2013-2016 UNITAID led a project in 
collaboration with TB REACH, the African Society for Laboratory Medicine (ASLM), Interactive Research 
and Development (IRD), EXPAND-TB, and the Global Laboratory Initiative (GLI) to make the test more 
widely available in 21 countries. In total 237 machines and 1.46 million cartridges were provided and 
201,748 cases were detected, including 45,278 that were resistant to rifampicin. Unfortunately the 
project did not monitor treatment initiation and the health impact of the initiative is not known, 
however the enhanced capacity to detect drug resistance was noted by some countries to have 
increased awareness of MDR-TB.5 A new version of the test (Xpert® MTB/RIF Ultra) has recently been 
launched which is claimed to have increased sensitivity for diagnosis and improved accuracy for 
detection of rifampicin resistance.6  A multicentre study reported increased sensitivity particularly 
among paucibacillary cases, but with a concurrent loss of specificity from 98% to 96%.7  Detection of 
rifampicin resistance was the same for both versions of the test (95%). The new Xpert® MTB/RIF Ultra 
cartridge was endorsed by WHO as a replacement for the Xpert® MTB/RIF cartridge in March 2017.8   
Particularly encouraging is the reported increased capacity to detect tuberculous meningitis where 
Xpert® Ultra sensitivity was 70% (95%CI 47-87) for probable or definite tuberculous meningitis 
compared with 43% (95%CI 23-66) for Xpert® MTB/RIF and 43% (95%CI 23-66) for culture.9    
The Alere Determine LAM TB test is a low-cost rapid lateral flow device for use at the bedside or in a 
clinic which has been shown to improve survival in hospitalised patients with low CD4 counts when 
there are limited other bacteriological tests available.10  It has been endorsed by the WHO.11  
Screening for latent tuberculosis infection (LTBI) offers opportunity to prevent progression to active 
disease and interferon release assays (IGRAs) are used to this end in low tuberculosis prevalence 
settings.12 However their inability to differentiate LTBI from active disease led the WHO not to endorse 




for predicting progression to active disease, relapse following treatment or protection following 
vaccination.   
 
DETECTING DRUG RESISTANCE 
MDR-TB and XDR-TB are increasingly reported worldwide. Prompt access to effective treatment is vital 
to prevent onward transmission and inhibit the emergence of resistance to further drugs during 
inadequate therapy. Phenotypic culture based methods remain the mainstay of drug susceptibility 
testing at reference laboratories but they are slow, taking weeks and require stringent microbiology 
safety precautions. There is no consensus on methodologies, which vary across laboratories and for 
some drugs the link between microbiological break point and clinical efficacy remains uncertain.13  In 
2017 WHO convened an expert meeting to discuss susceptibility testing for second line drugs and has 
subsequently recommended changes in the critical concentrations for some drugs.  
Drug resistance in MTB is caused by mutations in the bacterial genome that affect drug targets or 
enabling enzymes. Single nucleotide polymorphisms (SNPs) are the most frequently observed type of 
mutation. These small changes in the DNA sequence can easily be detected following amplification and 
they provide a rapid and accurate means of assessing of resistance to rifampicin. Line Probe Assays 
(LPA), where following PCR of target regions the amplicons are interrogated by membrane-bound 
probes are available from several manufacturers.  LPA are available for rifampicin and some of the other 
first and second line drugs.14  There are a number of other tests in development and the pipeline of 
molecular tests for resistance is summarised in Table 1. Three technologies (Cepheid Xpert® Ultra, 
Genedrive MTB/RIF and the Truenat MTB) have been designed for use at the level of a clinic with 
microscopy facilities; the remainder are expected to be used in referral laboratories. Gene sequencing is 
being increasingly used to detect MTB drug resistance as it affords a greater level of accuracy.13    
The Xpert® Ultra and Line Probe Assays have reported high sensitivities when testing for rifampicin 
resistance directly from smear positive sputum. Sensitivities are lower for other tuberculosis drugs, due 
in part to the large number of loci potentially involved in resistance which exceed the testing capacity of 
these simple molecular devices. A further technology related problem is the recording of false positives 
when the test is unable to discriminate silent mutations, an example of which is the substitution 
TTC/TTT in codon 514 of the rpoB gene which does not result in resistance to rifampicin.15 Resistance 




second line and newer drugs used to treat MDR and XDR-TB. To accelerate progress in this area an 
international consortium of researchers and international agencies, the ‘ReSeqTB initiative’ 
[https://platform.reseqtb.org/] has been established to create an open access platform.  Consensus 
methodology for interpreting the association between mutations and phenotypic drug-resistance has 
been published.16    
A new cartridge for the Cepheid GeneXpert is being developed that tests for resistance to isoniazid and 
some of the second line drugs.17 A prototype cartridge, when compared to phenotypic tests at sites in 
China and South Korea, had sensitivities for detecting resistance to isoniazid of 83·3% (95%CI: 77·1,88·5), 
88·4% for ofloxacin (95% CI: 80·2 , 94·1), 87·6% for moxifloxacin at a critical concentration of 0·5 μg per 
ml (95% CI: 79·0, 93·7), 96·2% for moxifloxacin at a critical concentration of 2·0 μg per ml (95% CI: 87·0, 
99·5), 71·4% for kanamycin (95% CI: 56·7,83·4), and 70·7% for amikacin (95% CI: 54·5, 83·9). The 
specificity of the assay was 94·3% or greater for all drugs except moxifloxacin which had a specificity of 
84·0% (95% CI: 78·9, 88·3) at a critical concentration of 2·0 μg per ml.17 
A recent large genome wide association study (GWAS) of MDR and XDR-TB found capacity to detect 
resistance to ethionamide, pyrazinamide, capreomycin, cycloserine and para-aminosalicylic acid was 
enhanced by the inclusion of insertions and deletions.18  This suggests simple SNP detection may not 
prove adequate for these drugs and more sophisticated molecular devices may be required. Next 
generation sequencing (NGS) and analysis of the whole genome may eventually become the reference 
standard for drug resistance identification.  Reduced costs and the establishment of high throughput 
sequencing centres and easy-to-use analytical tools has greatly increased access to NGS and it is 
currently being implemented as a routine service in several countries.  However, in most high burden 
countries it remains a research tool with the analysis performed overseas.  Proof of principle for NGS 
directly from sputum has been demonstrated but for comprehensive analysis the need to first isolate 
and culture the organism to obtain sufficient bacterial DNA hinders its application to patient 
management.19,20 
 
TUBERCULOSIS DIAGNOSTICS PIPELINE 
Figure 2 depicts the new diagnostics pipeline. There are a number of online resources that track 
progress in the development of new diagnostics for tuberculosis, including from the Treatment Action 




blog/unitaid-publishes-latest-tb-diagnostic-technology landscape/#en] and a dynamic website 
established by the Foundation for New Innovative Diagnostics -FIND [https://www.finddx.org/dx-
pipeline-status/].   They reveal that most novel technologies reported as ‘in development’ are not yet 
close to the market, being either studies of feasibility or early validation of prototype devices.14  Figure 3 
shows the top ten priorities for diagnostics development. Test developers face considerable technical 
challenges arising from the pathology of tuberculosis disease. Traditional methods of detecting 
infectious agents via unique biomarkers have failed for tuberculosis due to the complex and variable 
host immune response and the paucity of bacteria in clinical samples. Novel approaches being 
investigated include testing breath for tuberculosis metabolites and the application of nanotechnology 
and microfluidics to increase detection capacity and reduce hands on sample manipulation. Promising 
result have been reported on the use of new more sensitive technology to detect LAM 22 and circulating 
antigen peptides.23  Those favouring measurement of host response biomarkers will likely require novel 
platforms that detect multiple proteins. Similarly, antigen detection may require technology capable of 
assessing molecules of variable size and composition while remaining both easy-to-operate and 
affordable.  
Table 2 lists a range of new tests under development not based on the detection of nucleic acids.    
Undergoing evaluation for regulatory approval and closest to launch are competitors for the Xpert® 
MTB/RIF Assay.  These are devices aimed at low tech microscopy centres or high throughput 
instruments with extended drug resistance detection aimed at the reference laboratory.  Most tests are 
sputum-based but some aim to utilize blood or urine which might detect extra-pulmonary tuberculosis 
and childhood cases who fail to expectorate sputum.  Devices are now being designed to run on 
batteries and aim for a level of robustness that obviates the problems caused by dust and temperature 
extremes. This includes a portable version of the GeneXpert, The ‘Xpert Omni’. However, unforeseen 
technical challenges have delayed the development of the product and performance data is awaited.   
To aid prospective test developers and manufacturers a web-based compendium of available resources 
has been compiled.  The TB Diagnostics Pathway [www.tbdxpathway.org] outlines the steps needed for 
product development from market research and the development of a business plan through to product 
launch. It includes target technical profiles for tuberculosis diagnostic tools prioritised by the WHO and 
gives details of specimen banks that can provide samples for validation studies.  
Recent advances in communication technologies and cloud-based data management systems have 




‘connectivity’ allows automated reporting of results to the health system and enables monitoring to aid 
quality assurance measures and stock control.24 The importance of integration across devices and 
diseases and the need to maintain confidentiality has spurred the development of national guidelines in 
many countries that test developers need to be cognisant of when designing connectivity software.  
Though still in its infancy it is anticipated that the new technology will revolutionise data collection for 
monitoring tuberculosis incidence and the emergence of drug resistance.  
 
HOST BIOMARKER UPDATES 
The measurement of levels of host immune response molecules is a complimentary strategy to the 
detection of intact MTB or its products. The presence of host markers in accessible samples such as 
peripheral blood, saliva or urine, would be of great advantage in detecting paucibacillary disease, 
extrapulmonary disease or where sputum expectoration is problematic, such as in young children. A 
feature of the adaptive immune response is antigen specificity, where accelerated and enhanced 
responses follow prior antigen sensitization, allowing association of measured responses with specific 
MTB antigens. Circulating antibodies against pathogen products are readily measurable in ex vivo blood 
samples by ELISA or similar assays to reflect humoral immune responses, but performance of serological 
commercial assays has been poor, leading to a WHO advisory against the use of the currently available 
tests.25  
Cell-mediated immune responses require stimulation of lymphocytes prior to measurement of changes 
in the expression of activation markers or effector molecules, like co-stimulatory cell surface molecules 
or secreted molecules, including cytokines. Such stimulation assays require significant laboratory 
infrastructure and expertise and take at least several hours to days to produce results. Examples of such 
include the interferon gamma release assays (IGRAs) and also a range of host marker signatures 
including host gene expression, protein, metabolic and other host markers. Although there are currently 
no validated diagnostic tests based on these host markers, recently promising host marker biosignatures 
have been identified and are in clinical evaluation. Measurement of circulating soluble markers other 
than antibodies from either the innate (antigen non-specific, rapid response arm of the immune system) 
or adaptive immune system is also possible in accessible sample types and has the additional advantage 
of allowing testing without time-consuming stimulation assays. However, the specificity of such 




chronic insults to the immune system. Interpretation of such measurements will have to be within a 
well-defined clinical context. One approach to increase disease relatedness is the use of host marker 
signatures, rather than single markers.26 Several host signatures are at early stages of development or 
trial phase as possible new tools for tuberculosis diagnosis (Table 3).  
Host gene expression 
Several studies have explored the utility of host transcriptional biosignatures as diagnostic candidates, 
as well as biomarkers for prediction of the risk of future development of tuberculosis  disease. Genome-
wide transcriptional biosignatures detected in whole blood have been the most promising. Some groups 
have combined transcriptomic and proteomic approaches to explore progression to active tuberculosis 
disease.27 A predominantly neutrophil-driven type I Interferon dominated 86-gene whole blood 
transcriptional MTB signature was reported by Berry et al.28 The Fc gamma receptor 1B (FCGRIB) gene 
was found to be highly expressed in tuberculosis patients and in combination with four other genes 
(CD64, LTF, guanylate binding protein 5 and Granzyme A), discriminated between tuberculosis disease 
and LTBI with high sensitivity and specificity (94%  and 97% respectively) in smaller, case-control 
studies.29    
Kaforou and co-workers, investigated blood transcriptional biosignatures in individuals with active 
tuberculosis, LTBI or other diseases and identified a 44-transcript signature, which distinguished culture 
confirmed tuberculosis from other diseases with a sensitivity of 100% and specificity of 96% in a case-
control study,30 whereas Laux da Costa et al31.,  building on the findings of the earlier work by 
Maertzdorf et al,  compared the expression profiles of granzyme A, guanylate binding protein 5 and Fc 
gamma receptor 1A (CD64) genes in blood samples from patients with tuberculosis disease, asthma or 
non- tuberculosis pneumonia.31 A combination of the three genes discriminated between active 
tuberculosis disease and the other conditions with a sensitivity of 93% and specificity of 95%.31 
Sutherland et al. took the work further and evaluated the biomarkers identified by Maertzdorf et al.41 
and other mRNA transcript signatures in 523 study participants from four different African countries 
using the reverse transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) technique. 
CD64 was confirmed as a useful marker for tuberculosis disease irrespective of HIV infection and study 
site.32  CD64 in combination with three other genes diagnosed tuberculosis disease with a sensitivity of 
88% and specificity of 75% in another study.33  Bloom et al.34 compared the blood genome-wide 




pneumonia, lung cancer and healthy controls in a small study. Although there was significant overlap 
between transcriptional signatures obtained in tuberculosis and sarcoidosis patients in comparison to 
other patient groups, 144 transcripts distinguished tuberculosis from other diseases with sensitivity 
>80% and specificity >90%.34  
Anderson et al. evaluated mRNA transcript signatures in children with suspected tuberculosis from 
South Africa, Kenya and Malawi and compared with the profiles of children with LTBI and other 
diseases.35 A 51-transcript biosignature, diagnosed culture-confirmed tuberculosis disease in the 
validation sample set with a sensitivity of 82·9% (95% CI, 68·6 to 94·3) and specificity of 83·6% (98% CI, 
74·6 to 92·7). There are multiple studies describing mRNA transcript candidate markers for tuberculosis  
disease, including in silico conducted studies on published data sets and most of the signatures 
identified in these studies seem promising (accuracy >80%). However, the common limitation amongst 
these studies is that most of these, even those performed at multiple sites, still employed a case-control 
design and are at most phase II diagnostic studies.36 Most of these have small sample sizes and have 
been at single study sites, due to the high costs involved in properly designed multisite phase III 
diagnostic studies, including the relatively high costs of RNA sequencing, followed by RT-PCR validation. 
There is therefore a need to validate the candidate transcript signatures that have so far been identified 
in prospectively recruited patients with suspected tuberculosis, and in multiple settings.36 Such 
approaches would also have to be performed on rapid test platforms that would require minimum 
training, preferably laboratory-free inexpensive technology, to be of value in high burdened, resource-
constrained settings. 
A study of South African adolescents by Zak and colleagues, identified a 16 gene transcript signature, 
which discriminated between adolescents who would subsequently progress or not progress to active 
tuberculosis in a high incidence setting. The signature had a sensitivity of 66·1% (95% CI: 63·2,68·9) and 
specificity of 80·6% (95% CI:79·2,82·0), with enhanced sensitivity closer to the time of tuberculosis  
diagnosis. When evaluated on samples from South African and Gambian household contacts of active 
tuberculosis  cases, the sensitivity of the correlate of risk (CoR) signature was 53·7% (95% CI:42·6,64·3) 
with a specificity of 82·8% (95% CI:76·7,86), on samples that were collected 12 months before the 
development of active tuberculosis  disease.26  This performance exceeds the predictive performance of 




positive individuals is the subject of a currently ongoing clinical trial 
[https://clinicaltrials.gov/ct2/show/NCT02735590].  
 
Host protein markers 
IGRAs are not useful in high burden settings, owing to the high prevalence of LTBI and the inability of the 
assays to discriminate between LTBI and active tuberculosis disease. Host markers other than interferon 
gamma that are produced in response to new or alternative MTB antigens have been investigated. 
Although multiple antigens and host markers showing potential were identified37, the performance of 
tests based on (often overnight) stimulation assays did not warrant the longer lag time to a result and 
were not suitable for point-of-care rapid diagnostic tests.  Yoon et al. reported on a point-of-care CRP 
finger-prick test as a screening tool for tuberculosis  disease in HIV positive individuals with CD4 counts 
≤340 cells/ml who were initiating ART in Uganda.33 This test diagnosed culture-confirmed tuberculosis 
disease with a sensitivity of 89% and specificity of 72%.38 However, CRP in combination with six other 
proteins diagnosed tuberculosis disease in individuals with suspected pulmonary tuberculosis disease in 
field sites situated in five African countries with a sensitivity of 93·8% and specificity of 73·3%, with CRP 
as a single maker performing best in HIV infected individuals.39 A six protein biosignature was also 
discovered through SOMAscan technology as screening tool for tuberculosis with a sensitivity of 90% 
and specificity of 80% in over 700 samples from various tuberculosis endemic settings.40  There are 
diagnostic tests reported to be in development utilizing various combinations of the reported markers, 
but data is not yet available on their performance.     
 
Metabolomic markers 
Various platforms including nuclear magnetic resonance (NMR) spectroscopy, gas chromatography time 
of flight mass spectrometry (GC-TOFMS), liquid chromatography high-resolution mass spectrometry (LC-
MS), ultra-high-performance liquid chromatography–electrospray ionization-quadrupole time of flight 
mass spectrometry (UHPLC-ESI-QTOFMS) have been employed to detect small metabolites that can 
differentiate between tuberculosis disease and other diseases. Although candidate metabolites and 
pathways have been emerging, the work done so far has been in mostly small, case-control studies and 
the diagnostic potential of these candidate metabolites is yet to be validated in large studies. Using NMR 
spectroscopy, Zhou and colleagues evaluated differences in the serum metabolic profiles of patients 




several differentiating metabolites between tuberculosis cases, LTBI cases and healthy controls.41  They 
identified 30 metabolites, 17 of which were expressed significantly higher in serum samples from the 
tuberculosis patients in comparison to controls.42 They later identified ketone bodies, lactate and 
pyruvate as metabolites with the most potential in discriminating between tuberculosis disease and 
other conditions including community acquired pneumonia, diabetes and patients with various 
malignancies in a follow-up study.43  In a proof-of-concept study, du Preez et al, employed an untargeted 
metabolomics approach to investigate host metabolites in sputum samples using two dimensional GC-
TOFMS. Although there was high variability in the metabolites identified in samples from different 
patients, candidate metabolites including fatty acids, mycolic acids and carbohydrates showed potential 
as biomarkers.44 Other investigators using LC-MS identified other metabolites including MTB-derived 
glycolipids and resolvins in plasma samples,45 urinary metabolites with potential as markers for 
tuberculosis treatment monitoring,46 with combinations between four plasma metabolites 
discriminating between tuberculosis patients and controls including patients with pneumonia (identified 
by UHPLC-ESI-QTOFMS) with sensitivities ≥ 70% and specificities ≥80%.47 More metabolic biomarkers are 
continuously being identified in plasma samples, e.g.  metabolites that are involved in the glucose, lipid 
and amino acid metabolism pathways.48 Although findings from these studies continue to provide useful 
information about our understanding of the host metabolic response to infection with MTB, and 
ultimately help in shedding more light on the intracellular survival of MTB,49 the potential of these 
approaches as tuberculosis diagnostics still has to be confirmed. Validated signatures will also have to be 
translated from the current mass-spectrometry platforms into tools that are appropriate for resource-
constrained, high burden settings. 
 
MiRNA   
Many investigators have evaluated the role of miRNAs as possible diagnostic biomarkers for tuberculosis  
disease. Zhang et al evaluated serum miRNA signatures discriminating between active tuberculosis  
disease, LTBI and healthy controls in a small sample size of 15 tuberculosis  patients and 82 controls. 
They identified different miRNAs that were up or down-regulated in tuberculosis patients (24 and 6 
respectively) and although two of these miRNAs (hsa-miR-196b and hsa-miR-376c) showed potential as 
tuberculosis diagnostic markers after validation by RT-PCR, the limited sample size and lack of a 
validation cohort limits the global applicability of the study’s findings.50  In a similar study conducted by 




using micro-arrays and validated by RT-PCR, a 3-marker miRNA signature diagnosed active tuberculosis  
disease (tuberculosis  vs LTBI controls) with a sensitivity of 91% and specificity of 88%. 51 In another 
study, 29 miRNAs were found to be differentially expressed between tuberculosis patients and controls, 
with three of the miRNAs discriminating between tuberculosis  disease and healthy control patients with 
AUCs between 0·69 and 0·97 after validation by RT-PCR.52  All of these small, case-control studies 
require validation in larger cohort studies.  
 
Medical Imaging 
Chest X-ray can serve as triaging or screening tool for pulmonary, miliary, pleural and pericardial 
tuberculosis and can potentially close the case-detection gap when used in appropriate algorithms. It 
can identify patients in need for bacteriological examination and can provide important information 
where bacteriological confirmation is unhelpful. It is, however, not widely available in resource-
constraint settings. Radiography, which made a major contribution to the eradication of tuberculosis in 
well-resourced countries of Europe and North America, has become a more feasible option in settings 
with poor infrastructure with the introduction of digital systems. Software for automated reading is 
available which provides high throughput with reduced reliance on radiologists and the technology is 
being used to triage patients during case finding and to assist with prevalence surveys.14  More 
sophisticated imaging methods such as computed tomography scanning (CT) offers enhanced sensitivity 
and fluorodeoxyglucose positron emission tomography/CT (FDG PET/CT) may be used for assessing 
treatment response, but such specialised instrumentation remains beyond the reach of the majority of 
tuberculosis patients.53  
 
CHALLENGES AND NEEDS 
Improved tools for tuberculosis case finding and detection of drug resistance remain top priorities of 
WHO and the STOP-TB Partnership. Progress is being made but some key research questions for the 
development of priority diagnostic tests remain to be resolved (see Table 4).  Validation and evaluation 
of new technologies is ongoing, with more tests in the pipeline.  The ideal test should provide both high 
sensitivity and specificity but this is not always possible and compromises may have to be made. The 
accuracy of a new test should be non-inferior to the tests already available but lower sensitivity might 




with poor access to traditional clinic or laboratory-based health services. High specificity is required if a 
test is used to initiate anti-tuberculosis therapy but lower specificity can be tolerated when the device is 
to be used for triaging patients or for community-based screening.  Target product profiles published by 
WHO propose a specificity of 98% for a diagnostic test but a minimum of 70% if a follow-up 
confirmatory testing will be undertaken.54 The reported biomarker studies suggest that it may be 
possible to reach the desired performance targets but for maximum performance multiple markers shall 
need to be examined. Test developers face two major challenges when developing novel biomarker-
based tests. The first is that commercial pressures may prevent selection of the optimum panel of 
biomarkers. Patenting of biomarkers is common practice and competition to be the first-to-market is a 
powerful disincentive to cooperation.  The second challenge is that of measuring multiple markers 
across a broad range of concentrations or in very low concentrations. The detection platforms currently 
used are expensive and unsuitable for use at the point-of-need in countries with a high burden of 
tuberculosis. When asked how much it would cost to acquire or develop a new detection platform for a 
novel diagnostic test industry representatives provided estimates of between 3 and 20 million USD.55 
This was in addition to estimated research costs of between 3 and 8 million USD.   Thus, although the 
long term prospects for biomarker-based diagnosis of tuberculosis appears positive these badly needed 
tests will only be attained if sustained funding is available.   
Aside from the biological and technical challenges of creating novel diagnostic devices for tuberculosis 
there are considerable operational, economic and organisational barriers to be overcome. Figure 1 
presents key stages in production and adoption of a novel tuberculosis test, a process that may take 
over 10 years and cost in excess of USD 100,000,000.  Preparing a new test for market entry may cost 
more than was spent on developing the device. Studies of test performance must be undertaken in 
populations of intended use to provide evidence for regulatory approval and WHO endorsement. The 
lack of a credible gold standard for tests that detect extra-pulmonary forms of tuberculosis is a 
considerable hindrance. Reliance on sputum based tests is not appropriate and there is a need to 
increase capacity for diagnosing extra-pulmonary tuberculosis to enable accurate estimates of test 
accuracy.   
Previously there were few diagnostic options for the beleaguered tuberculosis programs to choose from 
but there will soon be a range of tests and technologies available that appear promising. Shelf life and 




and sample throughput capacity. Test performance, predictive value and cost effectiveness may vary by 
geographic setting or level of the health system due to differing local environmental, demographic and 
epidemiological factors. There are currently few data comparing test performance and even less on the 
potential impact and cost benefits.  What little data there is often comes from studies involving the 
developer of the test and one of the greatest challenges currently facing the tuberculosis  community is 
how to fund and organise independent assessment of new technology to maximise the benefits for 
tuberculosis control.     
CONCLUSIONS 
Reliance on passive case finding of infectious cases has failed to halt the pandemic and it is now 
recognised that improved diagnostic technology will not by itself reduce transmission unless 
interventions are implemented to enable earlier detection and treatment. To eradicate the disease 
active case finding and screening strategies will be needed and community involvement will be crucial, 
particularly in the less well-resourced countries. This will require a paradigm shift from national 
tuberculosis control programs and their supporting donor agencies who have long advocated clinic 
based detection.  In their Tuberculosis Control Report of 2017 the WHO note that insufficient gains have 
been made and the STOP TB partnership continues to call for increased political commitment and 
increased funding. 
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Figure 3    
Top 10 priorities for tuberculosis diagnostics development   
 
1. Affordable accurate rapid diagnostic devices for use at the point of care   
2. Screening devices for community based case finding or triaging patients in the clinic 
3. Non-sputum based tests for sputum scarce patients and extra-pulmonary tuberculosis 
4. Validated diagnostic tests for tuberculosis in children 
5. Rapid tests for drug resistance to guide the treatment of drug resistant tuberculosis.  
6. Tests to predict progression from latent tuberculosis infection (LTBI) to active tuberculosis 
disease and treatment failure/reactivation 
7. Tests to predict vaccine efficacy, to shorten and reduce costs of evaluating new vaccines 
8. Independent clinical performance studies to produce evidence for national regulatory approval 
and WHO endorsement 
9. Independent studies to assess impact on health outcomes and on the local health system 
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